Theobromine for the treatment of persistent cough: a randomised, multicentre, double-blind, placebo-controlled clinical trial.

ABSTRACT:

Background

To investigate the effect of BC1036 on health-related quality of life (QOL) in subjects with persistent cough. The secondary objective was to investigate the effect of BC1036 on subjective cough severity.

Methods

This was a randomised, multicentre, double-blind, placebo-controlled, parallel-group study in 289 subjects with persistent cough. Subjects received BC1036 or placebo twice daily for 14 days. The primary endpoint comprised cough-related QOL assessed using the validated Leicester Cough Questionnaire (LCQ) at Day 14. Secondary endpoints comprised the LCQ scores at Day 7 and Day 28, cough severity VAS scores at each visit and pulmonary function tests.

Results

At baseline, mean total LCQ score in the BC1036 group was lower (i.e., worse QOL) than placebo

SUBMITTER: Morice AH 

PROVIDER: S-EPMC5542984 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature